Small-cap biotech stock Lexicon Pharmaceuticals (LXRX) leapt as much as 17 percent in early trading on news that its lead therapy LX4211 showed positive top-line results in treating type 1
Lexicon Pharmaceuticals, Inc. (LXRX) shares are surging in Tuesday trading after the company announced its oral diabetes drug LX4211 met its primary endpoints in mid-stage clinical trial of Type
As we entered the fourth week of the trading year, we saw the S&P continue in its upward movement towards the close of January. On Jan. 26, we saw the S&P 500 jump out of the gates for an
Following the crowd isn't always a terrible thing. Despite what your kindergarten teacher may have insisted, there's safety in numbers. In investing, there's something to be said for watching
